Pre-Made Ledelabricin Alfa biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting PRG4(PROTEOGLYCAN 4) for drug discovery and mechanism of action (MOA) research

Pre-Made Ledelabricin Alfa biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting PRG4(PROTEOGLYCAN 4) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Proteoglycan 4 or lubricin is a surface-active mucinous glycoprotein secreted in the synovial joint that plays an important role in cartilage integrity. In healthy joints, lubricin molecules coat the cartilage surface, providing boundary lubrication and preventing cell and protein adhesion. Arthropathy occurring in patients with joint trauma, inflammatory arthritis or genetically mediated lubricin deficiencies have insufficient lubricin to prevent damage to articular cartilage. Ledelabricin Alfa is a human proteoglycan 4 isoform A variant, produced in Chinese hamster ovary (CHO) cells have been used to treat Arthropathy

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-885-1mg	1mg	3090
GMP-Bios-INN-885-10mg	10mg	Inquiry
GMP-Bios-INN-885-100mg	100mg	Inquiry
GMP-Bios-INN-885-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Ledelabricin Alfa biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting PRG4(PROTEOGLYCAN 4)
INN Name	Ledelabricin Alfa
Target	PRG4(PROTEOGLYCAN 4)
Format	Recombinant Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	PRG4 (lubricin, cartilage superficial zone proteoglycan, megakaryocyte stimulating factor) isoform A
VD LC	PRG4 (lubricin, cartilage superficial zone proteoglycan, megakaryocyte stimulating factor) isoform A
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Novartis (Basel Switzerland)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0